Mark S. Cohen – Chairman of the Board

Mark Cohen is a founder of Pearl Cohen Zedek Latzer Baratz LLP, Senior Partner, Chair of the Life Sciences Practice Group, and a member of the firm’s Executive Committee. Mark is admitted to the New York bar, and is a registered patent attorney in the United States with extensive international experience in patent prosecution, opinion, commercial transactional and licensing matters in the pharmaceutical, chemical, biological and medical device areas. His clients that he represents range from start-ups to Fortune 500 companies.  Mark was named by New York Metro Super Lawyers for 2019 as “Top Rated Intellectual Property Lawyer in New York”.  Mark was a Board Director of Masthercell Global Inc, a subsidiary of Orgenesis Inc. (NASDAQ: ORGS), prior to its acquisition in February 2020 by Catalant Inc. He was also Vice-Chairman of the Board and Chairman of Governance of at Akari Therapeutics, Plc. (NASDAQ: AKTX).

David Epstein – Independent Director

David R. Epstein is executive partner at Flagship Pioneering, chairman of Axcella Health, chairman of Rubius Therapeutics and chairman of Evelo Biosciences. David is also a board member at International Flavors and Fragrances and Integral Health. From early 2010 to mid 2016 he served as chief executive officer of Novartis Pharmaceuticals, a division of Novartis AG. Previously, David started and led Novartis’ Oncology and Molecular Diagnostic units. Under his leadership the company’s oncology business grew to the second largest in the world. David has more than 25 years of extensive drug development, deal making, commercialization and leadership experience on a global scale. Over the course of his career he led the development and commercialization of over 30 new molecular entities, including major breakthroughs such as Glivec, Tasigna, Gilenya, Afinitor, Cosentyx and Entresto. His teams developed 3 Prix Galien award winning medicines and he has developed several CEOs. He was named by FierceBiotech as one of the “25 most influential people in biopharma.”Early in his career, David was an associate in the strategy practice of consulting firm Booz, Allen and Hamilton. David holds a B.S. in pharmacy from Rutgers University College of Pharmacy (1984) and an M.B.A. in finance and marketing from the Columbia University Graduate School of Business (1987).

C. David Nicholson, PhD - Independent Director

Dr. Nicholson was Chief R&D Officer of Allergan until its acquisition by AbbVie in May 2020. Dr. Nicholson joined Allergan (then known as Actavis) as Senior Vice President, Global Brands R&D in August 2014. Previously, he served as Chief Technology Officer and EVP, R&D for Bayer CropScience from March 2012 to August 2014; Vice President of Licensing and Knowledge Management at Merck from 2009 to December 2011; and Senior Vice President, responsible for Global Project Management and Drug Safety at Schering-Plough from 2007 to 2009. From 1988 to 2007, Dr. Nicholson held various leadership positions at Organon, where he most recently served as Executive Vice President, Research & Development and was a member of the company’s Executive Management Committee. Dr. Nicholson serves on the Board of Directors of Actinium Pharmaceuticals and Science Exchange. He received a B.Sc. from the University of Manchester and his Ph.D. from the University of Wales.

Sushant Kumar, PhD - Co-Founder, Chief Executive Officer

Sushant has over 20 years of experience in business development, strategic advisory, and investing globally in the BioPharma sector. Prior to founding Tarus Therapeutics, he negotiated and consummated cross-border R&D transactions and targeted acquisitions within the healthcare industry. He was senior partner at Mehta Partners (predecessor firm Mehta & Isaly) and MP Asset Management, a healthcare-focused investment and strategic advisory firm, and managing director at Edison Group, an established investment research and consulting firm. Previously he was co-founder and managing partner at Ardana Capital, a pharmaceutical and biotechnology investment advisory firm. Sushant is also the co-founder of a targeted oncology company focused on genomically-defined cancers. Sushant received his Ph.D. in Molecular Biology from Rutgers Medical School and was American Cancer Society post-doctoral fellow at Harvard Medical School, where his research focused on the role of the ubiquitin-proteasome pathway in cancer.

Peter Molloy - Co-Founder, Executive Director

Peter Molloy has 25 years of experience creating, advising and investing in private and public companies, with a particular focus on the healthcare sector. He was previously the founder and CEO of Edison Group where he spent 15 years building the company into an international brand with a global team in excess of 100 people, recognized for its world class equity research platform, advisory services, and deep sector expertise. He remains a Director and principle shareholder of Edison. Peter is also the co-founder of various other companies including, most recently, Tarus Therapeutics. Peter’s earlier career includes a successful period as an institutional investor, most notably at Hermes Investment Management in London, managing a healthcare and technology focused small/mid-cap portfolio, and with a close involvement in Hermes’ shareholder activism initiatives. Peter currently sits on the Boards of several private and public companies and is also Chair of the African based charity Kick4Life. Peter graduated from Exeter University (UK) with a degree in Economics and is an alumni of London Business School. He holds the CFA (UK ) and FINRA Series 7.

Kasim Mookhtiar, PhD - Chief Scientific Officer

Kasim has over 25 years of experience in Drug Discovery and innovative pharmaceutical research, and building leading teams and companies in the pharma/biotech industry. He co-founded Advinus Therapeutics, a TATA Enterprise, where he began as the Chief Scientific Officer and eventually became its CEO. Previously Kasim was Vice President, New Drug Discovery Research, at Ranbaxy Laboratories. He began his career at the Bristol-Myers Squibb Pharmaceutical Research Institute in Princeton, where he was Director of Drug Discovery Department focused on Cardiovascular and Metabolic Diseases, Inflammation, and Cancer. Kasim is a graduate of the Indian Institute of Technology, Bombay, in Chemistry. He received his doctoral degree from the Institute of Molecular Biophysics, Florida State University, Tallahassee, followed by post-doctoral fellowship at the Yale University School of Medicine.